NIH’s 15% cap: a cost comparison and research outlook
The decision by the US government to cap the NIH grant overhead rate to 15% will likely underfund the country’s research institutions for their infrastructure relative to their international peers and the private sector. This move could jeopardize the country’s lead in the biological sciences.
Authors
- Mikael Elias (ORCID: https://orcid.org/0000-0003-0406-7539)
- Shina Caroline Lynn Kamerlin (ORCID: https://orcid.org/0000-0002-3190-1173)
Institutions
- University of Minnesota (US)
- Georgia Institute of Technology (US)
- Biotechnology Institute (US)
Publication Details
- Journal
- EMBO Reports
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1038/s44319-025-00418-4
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 6.26